Biorestorative Therapies, Inc. (NASDAQ:BRTX) Shares Shorted: Short Interest Up 146.3% in October

Posted by Tyrone Williams on Nov 13th, 2026

Biorestorative Therapies, Inc. (NASDAQ:BRTX – Get Free Report) was the target of a large growth in short interest in October. As of October 30th, there was short interest totaling 36,404 shares, a growth of 146.3% from the October 15th total of 14,778 shares. Based on an average daily volume of 38,359 shares, the days-to-cover ratio is currently 0.9 days. Approximately 3.1% of the shares of the stock are sold short.

Biorestorative Therapies Stock Down 1.7%

NASDAQ:BRTX traded down $0.03 on Friday, hitting $1.48. The stock had a trading volume of 5,997 shares, compared to its average volume of 292,548. The company has a fifty day moving average price of $2.03 and a two-hundred day moving average price of $5.51. Biorestorative Therapies has a 1-year low of $1.28 and a 1-year high of $28.99. The stock has a market cap of $2.04 million, a price-to-earnings ratio of -0.07 and a beta of 0.93.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Maxim Group cut Biorestorative Therapies from a “buy” rating to a “hold” rating in a report on Tuesday, October 6th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biorestorative Therapies in a report on Monday, August 24th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Reduce”.

Check Out Our Latest Report on Biorestorative Therapies

Biorestorative Therapies Company Profile

(Get Free Report)

BioRestorative Therapies, Inc. is a biotechnology company focused on developing regenerative medicine products using cell and tissue-based technologies. The company’s programs are intended to address conditions for which existing treatment options may be limited, including musculoskeletal and metabolic disorders. Its lead product candidate, BRTX-100, is an autologous cell therapy developed from a patient’s own bone marrow and designed to treat painful lumbar disc disease, including chronic lower-back pain associated with degenerated discs.